Amgen's $1.3 Bil. Acquisition Of Tularik Would Yield Two Late-Stage Oncologics
This article was originally published in The Pink Sheet Daily
Executive Summary
Tularik would broaden Amgen's oncology portfolio to small molecules with compounds for hepatocellular carcinoma, and esophageal and gastric cancers. The deal is one-tenth the size of Amgen's last acquisition – the $10 bil. Immunex purchase.